US 11,905,522 B2
Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity
Dmitry Dmitrievich Genkin, Saint Petersburg (RU); Georgy Viktorovich Tets, Saint Petersburg (RU); and Viktor Veniaminovich Tets, Saint Petersburg (RU)
Assigned to CLS THERAPEUTICS LIMITED, Saint Peter Port (GG)
Filed by CLS THERAPEUTICS LIMITED, Saint Peter Port (GG)
Filed on Jan. 15, 2019, as Appl. No. 16/248,245.
Claims priority of provisional application 62/617,879, filed on Jan. 16, 2018.
Prior Publication US 2019/0241908 A1, Aug. 8, 2019
Int. Cl. A61K 48/00 (2006.01); C07H 21/04 (2006.01); C12N 15/63 (2006.01); C12N 15/00 (2006.01); C12N 15/86 (2006.01); C12N 9/22 (2006.01); A61K 38/46 (2006.01); A61P 35/04 (2006.01); A61P 25/28 (2006.01); A61P 1/16 (2006.01); C07K 14/005 (2006.01); G01N 33/53 (2006.01); C12Q 1/68 (2018.01); A01K 67/00 (2006.01); A61B 5/00 (2006.01); A61B 17/00 (2006.01)
CPC C12N 15/86 (2013.01) [A61K 38/465 (2013.01); A61K 48/005 (2013.01); A61K 48/0058 (2013.01); A61P 1/16 (2018.01); A61P 25/28 (2018.01); A61P 35/04 (2018.01); C07K 14/005 (2013.01); C12N 9/22 (2013.01); C12Q 1/68 (2013.01); G01N 33/5308 (2013.01); A01K 2207/12 (2013.01); A01K 2227/105 (2013.01); A01K 2267/0331 (2013.01); A61B 5/4848 (2013.01); A61B 2017/00893 (2013.01); C12N 2750/14122 (2013.01); C12N 2750/14143 (2013.01); C12N 2750/14145 (2013.01); C12N 2830/008 (2013.01); G01N 2333/435 (2013.01); G01N 2800/7028 (2013.01)] 6 Claims
 
1. A method for inhibiting growth of a primary tumor in a subject having a cancer accompanied by accumulation of cell free DNA (cfDNA) in the hepatic porto-sinusoidal circulation of the subject, said method comprising administering to the subject a therapeutically effective amount of a recombinant adeno-associated virus (rAAV) expression vector comprising (i) a capsid protein and (ii) a nucleic acid comprising a promoter operably linked to a nucleotide sequence encoding an enzyme which has a deoxyribonuclease (DNase) activity, wherein the promoter is a liver-specific promoter, wherein the nucleic acid comprises the sequence of SEQ ID NO: 30 or SEQ ID NO: 31, and wherein the administration of the rAAV vector results in inhibiting growth of the primary tumor in the subject.